SOHO Brazil 2022

https://rvmais.iweventos.com.br/site/sintoma2022

 

SOHO Brazil 2022
Avatar

SOHO Brazil 2022 on Refractory ALL: What Is the Precise Time to Indicate CAR-T? The Golden Window That Cannot Be Missed

By SOHO Brazil 2022 FEATURING Michael Bishop, Phillip Scheinberg
By SOHO Brazil 2022 FEATURING Michael Bishop, Phillip Scheinberg
0 views
August 30, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi

Featured Video

24:08
Indy Hematology Review

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Feat. A. Tefferi
Leukemia
23:10
SOHO Brazil 2022

SOHO Brazil 2022: All You Need to Know (Until Now) About Targeted Th…

Feat. K. Pratz, P. Scheinberg
32:48
SOHO Brazil 2022

SOHO Brazil 2022 on Refractory ALL: What Is the Precise Time to Indi…

Feat. M. Bishop, P. Scheinberg
16:45
SOHO Brazil 2022

SOHO Brazil 2022 on CLL: The PI3K Inhibitors, the "Not-So-New K…

Feat. N. Jain, P. Scheinberg
20:09
SOHO Brazil 2022

SOHO Brazil 2022 on CLL: The BTK Inhibitors That Continue to “Heat-U…

Feat. N. Jain, P. Scheinberg
22:54
SOHO Brazil 2022

SOHO Brazil 2022 on Ph+ ALL: Is the Combination With TKIs Curing Pat…

Feat. J. Ribera, P. Scheinberg
20:04
SOHO Brazil 2022

SOHO Brazil 2022 on High-Risk AML: Is Conventional Chemo Still the B…

Feat. D. Pollyea, P. Scheinberg
20:23
SOHO Brazil 2022

SOHO Brazil 2022 on Doublets & Triplets With Venetoclax in AML: …

Feat. D. Pollyea, P. Scheinberg
26:48
SOHO Brazil 2022

SOHO Brazil 2022 on CLL: Do BTKi + BCL2 Inhibitors Need a Partner?

Feat. N. Jain, P. Scheinberg
25:29
SOHO Brazil 2022

SOHO Brazil 2022: Can Someone Be Destined to Develop AML? Understand…

Feat. L. Godley, P. Scheinberg